       Document 0275
 DOCN  M9640275
 TI    [Interferons in the therapy of solid tumors]
 DT    9604
 AU    Tomao S; Mozzicafreddo A; Raffaele M; Romiti A; Papo MA; Campisi C;
       Istituto Nazionale per la ricerca sul cancro, Policlinico Umberto; I di
       Roma.
 SO    Clin Ter. 1995 Aug-Sep;146(8-9):491-502. Unique Identifier : AIDSLINE
       MED/96120217
 AB    Belonging to the vast family of cytokines, interferons (IFN) have
       recently been widely investigated concerning their possible clinical
       applications, both in virology and oncology. In this field results have
       been quite mixed but definitely encouraging. The best achievements have
       been obtained in hematology, and particularly in the treatment of hairy
       cell leukemia and chronic myelogenous leukemia, but new perspectives
       have also opened in the therapy of solid tumors, especially in the local
       treatment of superficial bladder cancer and ovarian cancer, AIDS-related
       Kaposi's sarcoma and malignant melanoma. IFN have in certain cases
       showed an efficacy comparable to that of classic treatments but with
       lower toxicity, and in some tumors they have even improved the results
       obtained so far, especially in combined therapy. We have here gathered
       the most recent results concerning the use of IFN in the therapy of
       solid tumors in order to highlight the new therapeutic opportunities
       available to clinical oncology.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Antineoplastic
       Agents/TOXICITY/*THERAPEUTIC USE  Antiviral Agents/THERAPEUTIC USE
       Clinical Trials  Comparative Study  Cytokines/*THERAPEUTIC USE  English
       Abstract  Female  Human  HIV Infections/COMPLICATIONS
       Interferons/TOXICITY/*THERAPEUTIC USE  Leukemia/CLASSIFICATION/*DRUG
       THERAPY  Lymphoma/DRUG THERAPY  Male  Melanoma/*DRUG THERAPY/ETIOLOGY
       Neoplasms/CLASSIFICATION/*DRUG THERAPY  Sarcoma, Kaposi's/*DRUG
       THERAPY/ETIOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW LITERATURE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

